Merck-Daiichi, Roche-Roivant, base editors: BioCentury’s latest podcast
Merck’s $4.1B ADC deal. The $7.1B Telavant TL1A takeout. And the emerging base editor toolkit
By Jeff Cranmer, Executive Editor
October 24, 2023 12:20 AM UTC
Daiichi Sankyo Co. Ltd. (Tokyo:4568) has drawn more value from its antibody-drug conjugate pipeline via a $4 billion deal with Merck & Co. Inc. (NYSE:MRK). On the latest BioCentury This Week podcast, BioCentury’s editors analyze the deal in the context of the burgeoning ADC space and size up the assets that Merck is in-licensing as well as how the deal fits with Daiichi’s pipeline strategy.
The editors break down Monday’s $7.1 billion deal by Roche (SIX:ROG; OTCQX:RHHBY) for the Telavant subsidiary of Roivant Sciences Ltd. (NASDAQ:ROIV), the latest in the evolving TL1A space; and offer highlights from BioCentury’s deep dive into how academics and biotechs are expanding the therapeutic potential of base editors.
They also discuss some of the takeaways from last week’s free BioCentury-Oppenheimer webinar, “Creating High-Value Biotechs: The Tier Jumpers” and preview the upcoming CEO and investor event “Planning for the Biotech Breakout” that BioCentury is hosting with BIA on Nov. 14 on the sidelines of the Jefferies London Healthcare Conference.
